Soru

Zorluk: KolayPharmacologic Interventions

A 5454-year-old man with a history of stage 44 chronic kidney disease presents to the emergency department complaining of generalized muscle weakness and palpitations that started earlier today. His vital signs are stable, but his electrocardiogram reveals peaked T waves and widened QRS complexes. Laboratory results show a serum potassium level of 7.67.6 mEq/L. Arrange the following pharmacologic interventions in the most appropriate chronological sequence for the acute stabilization and management of this patient.

  1. 1Intravenous calcium gluconate
  2. 2Intravenous regular insulin and 50%50\% dextrose
  3. 3Oral sodium zirconium cyclosilicate

Cevap

The correct sequence for managing severe hyperkalemia with electrocardiographic changes is: 1) Intravenous calcium gluconate, 2) Intravenous regular insulin and dextrose, 3) Oral sodium zirconium cyclosilicate.
The correct sequence for managing severe symptomatic hyperkalemia prioritizes immediate life threats before definitive treatment. The first and most critical step is stabilizing the cardiac myocyte membrane with intravenous calcium gluconate to prevent fatal arrhythmias. Once the myocardium is protected, the second step is rapidly shifting potassium from the extracellular space to the intracellular space using intravenous regular insulin paired with dextrose. The final step is definitively removing excess potassium from the body, which can be accomplished using gastrointestinal potassium binders such as oral sodium zirconium cyclosilicate.

Adım Adım Çözüm

1
Identify the life-threatening condition and its immediate risk.
The patient has severe hyperkalemia with electrocardiogram changes (widened QRS complexes), indicating an imminent risk of ventricular arrhythmias.
Recognizing the severity dictates that immediate cardiac protection takes precedence over definitive potassium removal.
2
Select the initial cardioprotective agent.
Administer intravenous calcium gluconate.
Calcium antagonizes the membrane actions of hyperkalemia, stabilizing the cardiac conduction system without altering the serum potassium concentration.
3
Select the temporizing intracellular shifting agent.
Administer intravenous regular insulin and dextrose.
Insulin drives potassium into cells via the Na-K-ATPase pump, rapidly lowering serum potassium within minutes. Dextrose is given to prevent hypoglycemia.
4
Select the definitive elimination agent.
Administer a gastrointestinal potassium binder like oral sodium zirconium cyclosilicate.
This removes excess total body potassium over several hours to days, providing a permanent solution to the hyperkalemia.

Anahtar Kavram

Management sequence of severe symptomatic hyperkalemia
Bu soruyu puanla